Drug development: From concept to marketing!

Nephron - Clinical Practice

Volumn 113, Issue 3, 2009, Pages

  Tamimi, Nihad A M ^a   Ellis, Peter ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Clinical trials; Drug approval; Drug discovery; Drug safety

Indexed keywords

CERIVASTATIN; ORPHAN DRUG; ROFECOXIB;

CARCINOGENICITY; CHRONIC KIDNEY DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; GENITAL SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY; STANDARD; UNSPECIFIED SIDE EFFECT;

ANIMALS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MARKETING;

EID: 68349107959     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000232592     Document Type: Short Survey

References (12)

1. Tufts Center for the Study of Drug Development pegs cost of a new prescription medicine at $802 million. 2001. http://csdd.tufts.edu/ NewsEvents/RecentNews.asp?newsid=6 (accessed January 2, 2009).
2. Drug development: The short story 7. Cost of drug development. Network Science Corporation. http://www.netsci.org/scgi-bin/Courseware/projector.pl? Course-num=cour-se1&Filename=slide07.html (accessed January 2, 2009).
3. Drugresearch.com: Drug development costs hit $1.7 billion. 2003. http://www.drugresearcher. com/Research-management/Drugdevelopment-costs-hit-1. 7-billion (accessed January 2, 2009).
4. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715.
5. Protección de la propiedad intelectual para productos farmacéuticos: Qué es y por qué es esencial para la innovación en salud? Consideraciones a la luz del DR-CAFTA. http://www.amchamsal.com/uploaded/content/category/2000065261.pdf (accessed January 2, 2009).
6. Dutta A: Discovery of new medicines; in Griffin JP and O'Grady J (eds): The Textbook of Pharmaceutical Medicine. London, BMJ Books, 2002, p 25.
7. International Union of Pure and Applied Chemistry: Glossary of terms used in combinatorial chemistry, U-Z3. Research Triangle Park, International Union of Pure and Applied Chemistry. 1999. http://www.iupac.org/reports/1999/ 7112maclean/u-z.html (accessed January 2, 2009).
8. Rester U: From virtuality to reality -virtual screening in lead discovery and lead optimization: A medicinal chemistry perspective. Curr Opin Drug Discov Devel 2008; 11: 559-568.
9. Tweats DJ, Scales MDC: Toxicity testing; in Griffin JP and O'Grady J (eds): The Textbook of Pharmaceutical Medicine. London, BMJ Books, 2002, p 134.
10. Hall JE: The promise of translational physiology. Am J Physiol 2002; 283: 1235-1236.
11. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
12. What is the code of practice. http://www.pmcpa.org.uk/?q= whatisthecodeofpractice (accessed March 29, 2009).